In Vivo Model Development for Cytokine Release Syndrome

Protheragen offers comprehensive in vivo animal model development services for Cytokine Release Syndrome (CRS), supporting pharmaceutical and biotechnology partners in the evaluation of novel therapeutics. Our extensive portfolio of validated murine models enables precise recapitulation of CRS pathophysiology, providing robust platforms for preclinical efficacy and safety assessments.

Cytokine Release Syndrome is a critical, often life-threatening condition associated with immunotherapies and severe infections. Accurate animal models are essential for understanding CRS mechanisms and for preclinical testing of candidate drugs. Protheragen utilizes various strains of Mus musculus, including Balb/c, C57BL/6, NSG, and NSG-SGM3 mice, to mirror human immune responses and disease progression. These models are selected for their immunological profiles and compatibility with xenograft approaches, ensuring translational relevance to human CRS. Incorporating both biological and chemical induction methods, as well as humanized models, our offerings enable tailored studies that address diverse research objectives and regulatory requirements.

Biologically-Induced Models

Biologically-induced CRS models are established by administering agents such as anti-CD3 monoclonal antibodies or lipopolysaccharide (LPS) to stimulate robust immune activation and cytokine production. These models utilize immunocompetent mouse strains (e.g., Balb/c, C57BL/6) as well as immunodeficient strains (NSG, NSG-SGM3) for human cell engraftment. Advantages include reproducibility, rapid onset of CRS-like symptoms, and suitability for mechanistic and therapeutic studies. Primary applications include evaluating immunotherapeutic safety, dissecting cytokine signaling pathways, and screening anti-cytokine interventions.

Chemically-Induced Models

Chemically-induced models employ agents such as concanavalin A to provoke immune cell activation and trigger cytokine storms in mice. This approach is particularly valuable for studying T-cell mediated CRS and liver involvement. The methodology is straightforward, cost-effective, and yields consistent inflammatory responses. These models are ideal for investigating the efficacy of immunomodulators, hepatoprotective agents, and for mechanistic studies of T-cell driven cytokine release.

Humanized/Xenograft Models

Humanized or xenograft CRS models are developed by engrafting immunodeficient mice (such as NSG or NSG-SGM3) with human mononuclear cells, CD34+ hematopoietic stem cells, or human tumor cell lines (e.g., Raji B-lymphocytes). These models closely mimic human immune responses and are indispensable for evaluating human-specific immunotherapies, including CAR-T cell therapies and bispecific antibodies. Key advantages include high translational relevance, the ability to assess human cytokine profiles, and the suitability for efficacy and safety studies of cell-based therapies.

Protheragen provides end-to-end in vivo CRS model development services, encompassing model selection, study design, animal handling, dosing, sample collection, and comprehensive data analysis. Key efficacy endpoints include clinical scoring, survival analysis, body weight monitoring, serum cytokine quantification (e.g., IL-6, IFN-γ, TNF-α), hematological and biochemical profiling, and histopathological examination of target organs. Our analytical capabilities extend to multiplex cytokine assays, flow cytometry, bioluminescence imaging (for luciferase-tagged xenografts), and immune cell phenotyping. All studies are conducted under stringent quality control protocols, with validated SOPs, ethical compliance, and rigorous data integrity checks to ensure reproducibility and scientific validity.

By partnering with Protheragen, you gain access to a scientifically rigorous, client-focused team with deep expertise in CRS model development and preclinical pharmacology. Our flexible service offerings, advanced analytical platforms, and commitment to quality empower you to accelerate your research and confidently advance your therapeutic candidates toward clinical success. Contact us today to discuss your CRS modeling needs and discover how Protheragen can support your next breakthrough.